The synaptic inactivation of the opioid peptides [Leu5]-and [Met']-enkephalin occurs by extracellular metabolism rather than through re-uptake into neuronal or glial cells (see, e.g.. Turner et a/., 1985) . Synaptclsomal preparations predominantly hydrolyse and inactivate enkephalins at the Tyrl-Gly? bond, although much of this. activity is attributable to cytosolic aminopeptidases. In contrast, a major metabolite of [ Mets] enkephalin in the perfused rat brain in rirw (Craves P I a/., 1978) or in mouse brain striatal membranes (Malfroy et a/., 1978) is Tyr-Gly-Gly formed by the action of a membrane-bound peptidase capable of hydrolysing the Gly"-PheJ bond. The nature of the latter enzyme has provoked much controversy in the literature and has variously been attributed to angiotensin converting enzyme (peptidyl dipeptidase A, EC 3.4.. 15.1) (Swerts et a/., 1 9 7 9~; Benuck & Marks, 1979) , to a unique dipeptidyl carboxypeptidase (Malfroy et a/., 1978) and to the action of an endopeptidase (Blumberg et a/., 1981; Fulcher et al., 1982) . The lack of inhibition of enkephalin hydrolysis by captopril ruled out a significant role for peptidyl dipeptidase A in the inactivation of enkephalin (Swerts et a/., 1979b) and the novel inhibitor thiorphan (Roques et a/., 1980) was subsequently designed as a selective inhibitor of enkephalin metabolism. This compound not only prevented hydrolysis of the Gly3-PheJ bond of enkephalin in zitro but also protected [ Metlenkephalin released from brain slices (Patey er a/., 1981) . We have suggested that the brain enzyme hydrolysing the enkephalins may resemble kidney microvillar endopeptidase-24.1 I , a mammalian plasma membrane enzyme that is uniquely inhibited by phosphoramidon.
Abbreviations used : LH-RH. luteinizing hormone-releasing hormone (luliberin): a-MSH, a-melanocyte stimulating hormone; CCK, cholecystokinin; CNS, central nervous system. The availability of selective peptidase inhibitors and both polyclonal and monoclonal antibodies to endopeptidase-24.11 has allowed us to test this hypothesis and to extend a role for this enzyme to the metabolism of other neuropeptides at the cell surface.
Endopeptidase-24. I I
Endopeptidase-24.11 is an integral membrane glycoprotein which is highly concentrated in the renal brush border but it is not unique to the kidney nor to mammalian tissues (Turner & Dowdall, 1984) . The enzyme is characteristically inhibited ( K , = 2nM) by the thermolysin inhibitor, phosphoramidon (Kenny, 1977) . Certain structural similarities between thiorphan and phosphoramidon first suggested to us that the hydrolysis of the Gly3-PheJ bond of enkephalin in brain might be attributable to an activity resembling endopeptidase-24.1 I . Furthermore, the nature of the cleavage, on the amino side of a hydrophobic residue, was consistent with the known specificity of the enzyme. Homogeneous preparations of pig kidney endopeptidase were able to hydrolyse [Leu'lenkephalin ( K , = 8 6~~) and [Mets] enkephalin ( K , = 6 2~~) and in both cases hydrolysis occurred at the Gly3-PheJ bond and was inhibited identically by thiorphan or phosphoramidon (Fulcher et a/., 1982) . The hydrolysis of enkephalin by synaptic membranes from pig brain was also inhibited by thiorphan or phosphoramidon (Fulcher er al., 1982; .
Confirmation of the identity of the brain and kidney enzymes has relied upon immunological techniques ; Relton e t a / . , 1983; Almenoff & Orlowski, 1984) . A polyclonal antiserum to the kidney microvillar endopeptidase inhibited the hydrolysis of [~-Ala~,Leu~]enkephalin by synaptic membranes or kidney microvillar membranes in an identical fashion . A monoclonal antibody raised to the microvillar enzyme (Gee e t a / . , 1983) has been used successfully to purify pig brain endopeptidase-24.11 to homogeneity (Relton et al., 1983 ). An immunoadsorbent column containing the monoclonal antiVol. 13 body achieved essentially a single-step purification with a yield of approx. 1 pg of endopeptidase protein/g of striatum.
The overall purification was 24000-fold, a degree of enrichment that would have been difficult to achieve with conventional protein purification techniques. The enzyme appeared homogeneous after sodium dodecyl sulphate/polyacrylamide-gel electrophoresis, with an apparent subunit M , of 87000 (Relton et al., 1983) . This is lower than the values obtained for endopeptidase purified from pig kidney (89000) or pig intestine (94000). The enzymes from all three tissues have similar amino acid compositions and show apparent identity by Ouchterlony immunodiffusion. The small differences in subunit size appear to be due to differences in the degree of glycosylation (Relton et al., 1983) . It is likely that the polypeptide chain ( M , = 77000) represents the same gene product in these different cell types. Some of the properties of pig brain endopeptidase-24.11 are summarized in Table 1 .
Hydrolysis of neuropeptides by endopeptidase-24.1 I
Many biologically active peptides have blocked N-and Ctermini, e.g. gastrin, LH-RH and a-MSH, and therefore the action of an endopeptidase will commonly be required to initiate hydrolysis of a given peptide. Since the presence of an internal hydrophobic residue is a common feature of regulatory peptides, endopeptidase-24.11 is ideally situated to inactivate such peptides at the cell surface. We have therefore examined the potential of endopeptidase-24.11 to hydrolyse a range of possible neuropeptide substrates (Matsas et al., , 1984a . In particular we have compared the hydrolysis of substance P and sulphated cholecytokinin octapeptide (CCK-8) by kidney endopeptidase and by striatal synaptic membranes prepared from pig brain (Matsas et al., 1983, 19846) . The sites of hydrolysis of these peptides by the endopeptidase are listed in Table 2 . Substance P is hydrolysed at three internal sites, consistent with an endopeptidase action. The principal site of hydrolysis involved the Gly9-Leu10 bond. Phosphoramidon at 1 p~ was able to abolish completely the hydrolysis of substance P by synaptic membranes, suggesting a role for the endopeptidase in the inactivation of this neuropeptide . In the case of the sulphated form of CCK-8, hydrolysis was observed at the Gly-Trp but not the TrpMet bond (Matsas et al., 1984b) , in contrast to the observations of Deschodt-Lanckmann & Strosberg (1983) . In addition, the enzyme was able to release the C-terminal Phe-NH2 residue from CCK-8 and this was the favoured site of hydrolysis (Matsas et al., 19846) . A combination of phosphoramidon and bestatin was required to abolish the hydrolysis of sulphated CCK-8 by synaptic membranes, indicating an involvement of both endopeptidase-24.11 and aminopeptidases in the metabolism of this peptide, as is also the case for the enkephalins.
LH-RH, which is blocked at both N-and C-termini, contains several internal hydrophobic residues, and is hydrolysed in vitro by kidney endopeptidase-24.11. However, the hydrolysis of LH-RH by synaptic membranes is little affected by phosphoramidon, implicating an additional endopeptidase in the hydrolysis of this peptide. It is clear, therefore, that amino acid residues distant from the suscep- Fig. 1 . A wide range of peptides of diverse structures are metabolized and, in all cases, hydrolysis occurs at the bond involving the amino group of a hydrophobic residue (Table 2) . Of the substrates examined, LH-RH is hydrolysed least efficiently. The endopeptidase releases the dipeptide Phe-Leu from the C-terminus of [Le~~lenkephalin, which has led to the suggestion that the enzyme should be designated a peptidyl dipeptidase (Malfroy & Schwartz, 1982) . However, a critical examination of the nature of susceptible bonds reveals that the enzyme is a genuine endopeptidase (Fig. 1) . For example, enkephalins with a C-terminal extension, e.g. [Le~~lenkephalin-Argb, [Mets] enkephalin-Argb and [Met5]enkephalin-Arg6-Phe7, are metabolized at least as efficiently as the parent peptide with hydrolysis still occurring at the Gly3-Phe4 bond. C-Terminally amidated peptides, e.g. CCK, gastrin and substance P, are also hydrolysed. Substance P exhibits the lowest K,,, value of all the natural peptides that we have tested and there is little difference in the efficiency of hydrolysis of substance P and its non-amidated analogue. The efficiency of hydrolysis of bradykinin, neurotensin and cholecystokinin does not differ markedly from that of the enkephalins, suggesting that the physiological function of endopeptidase-24.11 is much wider than the trivial name 'enkephalinase' would imply.
Discussion
Specificity and inhibitor studies in vitro can provide only a guide as to the likely physiological substrates for a given peptidase. It is clearly important to know whether each peptidase is located in the synaptic membrane and with the ap- (1984a,b) . (1985) . DiMeC, is an analogue of substance P (pGlu-GIn-Phe-MePhe-MeGly-Leu-MetNH,) described by Sandberg et al. (198 1) .
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propriate orientation for it to have a physiological role in hydrolysing neuropeptides released at that site. That information is not yet available for any membrane peptidase. The physiological function of endopeptidase-24.11 must be viewed in the light of its wide distribution in mammalian tissues , many of which do not contain endogenous enkephalin. Substance P must be considered a candidate for hydrolysis by endopeptidase-24.11 in the CNS, although angiotensin converting enzyme (peptidyl dipeptidase A, EC 3.4.15.1) can also hydrolyse this substrate in vitro (Yokosawa et al., 1983; Cascieri et al., 1984; Erdos & Skidgel, 1985) . Techniques for evaluating the role of peptidases in the hydrolysis of neuropeptides have principally involved the use of selective inhibitors to block the metabolism of peptides released from brain slice preparations. Such studies have supported il role for both endopeptidase-24.11 and aminopeptidase in the inactivation of the enkephalins (de la Baume et al., 1982). However, such peptide-release experiments have a nurnber of drawbacks, and results from such experiments must be treated with caution (Meyer & Feuerstein, 1984) . Clearly, new techniques need to be developed for identifying critical peptidases in the metabolism of individual neuropeptides. We have suggested ) that a limited number of cell-surface peptidases mediate a wide range of functions and their cellular location, rather than peptide specificity, defines their roles at different tissue sites. The value of our immunological approach, using antibodies developed to renal peptidase antigens for characterizing CNS peptidases, has been vindicated in the case of endopeptidase-24.11 Relton (of al., 1983) and acknowledged by others who have applied our techniques in studies of synaptic membrane aminopeptidases (Schwartz, 1985) . The synaptic metabolism of neuropeptides can currently be interpreted adequately in terms of wellcharacterized membrane peptidases without the need to invoke the concept of 'neuropeptidases'.
We thank the Medical Research Council for support. Quite a few years ago, while studying the inactivation of bradykinin by kidney extracts, an enzyme in a particulate (microsomal) fraction of rat kidney was found to release the C-terminal dipeptide (Phe-Arg) of bradykinin (Erdos & Yang, 1967) . This enzyme, named kininase 11, was solubilized with deoxycholate and partially purified by gel filtration. It was subsequently also isolated from human plasma (Yang & Erdos, 1967) . Prior to that an ACE, was found in horse plasma (Skeggs et al., 1954 (Skeggs et al., , 1956 . ACE was shown to be a peptidyl dipeptidase (peptidyl dipeptidase A; EC 3.4.15.1) identical with kininase I1 after testing it with a variety of peptide substrates (Yang et al., 1970 (Yang et al., , 1971 .
Vane, Ferreira and their colleagues originally pointed out the importance of the lung in the metabolism of circulating peptides (Ferreira & Vane, 1967; Ng & Vane, 1967 , 1968 Vane, 1969) . The lung is a rich source of ACE and the enzyme is bound to the plasma-membrane of vascular endothelial cells (Ryan et al., 1976 ). Endothelial cells of extrapulmonary blood vessels also contain ACE (Kreye & Gross, 1971; Aiken & Vane, 1972; Rabito et al., 1972) .
Many other organs contain high concentrations of ACE where it is concentrated mainly in epithelial cells, e.g. the microvilli of the gut (Ward et al., 1980), kidney (Hall et al., 1976) , placenta (Johnson et al., 1984) and choroid plexus (Igic et al., 1977; Rix et al., 1981) . The enzyme was also detected in various parts of rat and human brain and in the pituitary gland (Yang & Neff, 1972; Poth et al., 1975) .
To localize ACE in tissues and organs by immunohistochemical techniques, the enzyme had to be purified in order to elicit a specific antiserum. The purification of ACE from human tissues was a more complex problem than the purification from organs of hog (Oshima et al., 1974; Nakajima et al., 1973) or rabbit (Cushman & Cheung, 1972; Das & Soffer, 1975) , since the human enzyme appears to be more hydrophobic than the animal variety. This leads to significant losses of activity during the purification procedures. By employing trypsin to solubilize ACE from a membrane fraction (Nishimura et al., 1977; Stewart et al., 1981) , and the technique of 'reverse immunoadsorption' (Weare et al., 1982) , the purification procedure was greatly simplified.
ACE in human kidney is 5-6 times more concentrated per weight than in the lung and it is bound to the brush border in the proximal tubules (Weare et al., 1982) . Presumably, ACE is a transmembrane peptidase with a hydrophobic anchor peptide inserted into the lipid bilayer of the plasma membrane (Erdos & Gafford, 1983) . The difference in M , between the membrane-bound enzyme and the enzyme solubilized with trypsin was shown with 'Western blotting'. ACE extracted from the renal membrane with detergent had a slightly higher M , value than the enzyme purified from kidney after trypsin treatment (Erdos & Gafford, Abbreviation used: ACE, angiotensin I converting enzyme. 1983). ACE extracted from cultured human endothelial cells with detergent also had a slightly higher M , value than the purified renal enzyme (A. R. Johnson & E. G. Erdos, unpublished work) . The difference in M , between the detergent-solubilized and trypsin-solubilized forms of the enzyme was less than 10000 and is very likely to be due to the removal of an anchor peptide by trypsin.
Although ACE in human lung and kidney originates from different types of cells (endothelial versus epithelial), the protein portions of the two enzymes appear to be similar or identical. Double immunodiffusion studies showed that both enzymes cross-react with antiserum raised against either the lung or the kidney enzyme (Stewart et al., 1981) . Differences, however, were found in the carbohydrate moieties (Weare et al., 1982) .
The antiserum against human ACE was used to localize it in tissues, including the central nervous system (Defendini et al., 1983) and to develop a radioimmunoassay procedure for the enzyme (Alhenc-Gelas et al., 1983). In the brain, as in other organs, ACE appears to be bound to plasma membranes. The choroid plexus is particularly rich in ACE (Igic et al., 1977) , where it is concentrated on the surface of cuboidal epithelial cells facing the cerebrospinal fluid (Defendini et al., 1982 (Defendini et al., , 1983 Rix et al., 1981) . The choroid plexus is in the immediate vicinity of the subfornical body, where angiotensin I1 exerts its very potent dipsogenic action. Thus, the presence of ACE in the choroid plexus may be more than coincidence. With the help of immunohistochemistry, ACE was also found to be in the subfornical body itself (Defendini et al., 1982 (Defendini et al., , 1983 . ACE was identified on dendrites of cells in various regions of the human brain, such as the globus pallidus and the substantia nigra. The dendroplasma was negative by the immunoperoxidase technique. Other structures, such as the magnocellular neurosecretory system of the hypothalamus, were also rich in ACE (Defendini et al., 1982 (Defendini et al., , 1983 .
The protein portions of ACE that originated from endothelial, epithelial, or neuroepithelial cells appear to be immunologically identical. This was shown with a direct radioimmunoassay of ACE (Alhenc-Gelas et al., 1983) using a homogeneous preparation of human lung ACE and extracts of caudate nucleus and globus pallidus (Fig. I) . The parallel lines obtained for ACE from different sources after a logit-log transformation of the displacement curves, indicate immunological identity (Defendini et al., 1983) .
We were puzzled by the location of ACE on the pallidonigral dendrites because it coincided remarkably well with the cellular distribution of substance P, a peptide not thought to be a substrate for ACE. A possible explanation for this phenomenon was obtained in studies on the substrate specificity of the human enzyme.
ACE cleaves a variety of peptides including angiotensin I, bradykinin, enkephalins and many different N-terminally protected tripeptides (Stewart et al., 1981) . Of the biologically active peptides, enkephalins are hydrolysed the fastest in vitro, but because of the high K,, the specificity constant (kcat./Km) is less favourable than that of bradykinin or angiotensin I (Table 1 ). Of the peptides tested, bradykinin has the highest 'affinity' for ACE (Table 1) .
